公司领导层变动 - 公司宣布两项关键领导层任命：Mike Hershkovitz先生被任命为全球销售副总裁，Sivan Matza女士被任命为董事会独立董事 [1] - Sivan Matza女士将同时在董事会薪酬委员会、审计委员会和财务报表审查委员会任职，并接替即将卸任的Limor Rosen女士 [1] - 董事会主席Tal Parnes代表公司感谢Limor Rosen的贡献，并欢迎Sivan Matza加入董事会 [6] 新任管理层背景 - Sivan Matza女士在一家领先的国际投资管理公司担任董事，监管数百亿美元资产，在全球金融、监管和会计方面拥有丰富经验 [2] - Mike Hershkovitz先生拥有近二十年在美国和国际医疗市场的领导经验，曾在美国强生公司等全球医疗技术机构担任高级商业职务 [3] - 公司首席执行官Dagi Ben-Noon认为，新任命的综合专业知识将成为公司下一阶段增长和执行的强大催化剂 [4][5] 公司业务与战略定位 - 公司是一家商业阶段的医疗设备公司，专注于先进的呼吸支持和实时血液监测解决方案 [7] - 其INSPIRA™ ART100系统已获得美国FDA批准在美国进行心肺转流，并在美国以外地区用于ECMO（体外膜肺氧合）手术 [7] - 公司正在开发下一代系统INSPIRA ART500，并推进其专有的HYLA™血液传感器平台，该平台可提供连续、无创的监测 [7] - 公司拥有多个已获批产品、不断增长的知识产权组合以及战略性的运营精简，在生命支持和医疗技术领域日益成为一个有吸引力的平台 [7]

公司领导层变动 - 公司任命Mike Hershkovitz先生为全球销售副总裁，并任命Sivan Matza女士为公司董事会独立董事[1] - Sivan Matza女士将同时在董事会薪酬委员会、审计委员会和财务报表审查委员会任职，接替即将离任的Limor Rosen女士[1] - Mike Hershkovitz先生将领导公司的全球销售战略和医院采用计划[3] 新任高管背景与职责 - Sivan Matza女士是一家领先的国际投资管理公司的董事，负责监督数百亿美元的资产，其在全球金融、监管和会计方面的经验将加强公司治理框架[2] - Mike Hershkovitz先生拥有近二十年在美国和国际医疗市场的领导经验，曾担任强生等全球医疗技术机构的高级商业职务[3] - 公司首席执行官Dagi Ben-Noon表示，新任命的综合专业知识是公司下一阶段增长和执行的有力催化剂[4][5] 公司业务与战略定位 - 公司是一家商业阶段的医疗设备公司，专注于先进的呼吸支持和实时血液监测解决方案[7] - 公司的INSPIRA™ ART100系统已获得美国FDA批准用于美国的心肺转流术以及美国以外的ECMO（体外膜肺氧合）手术[7] - 公司正在开发下一代系统INSPIRA ART500，旨在让患者在保持清醒和自主呼吸的同时进行氧合，并推进用于连续、无创监测的专有血液传感器平台HYLA™[7] - 公司拥有多个已获批产品、不断增长的知识产权组合以及战略性的运营精简，在生命支持和医疗技术领域日益成为一个有吸引力的平台[7]

RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Comp ...

RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Compa ...

RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Comp ...

Inspira delivered major milestones throughout and following the six months ended June 30, 2025, including the receipt of $49.5 million in binding purchase orders, clinical validation in leading hospitals, 97.35% accuracy for its HYLA blood sensor, and strategic patent protection, underscoring accelerating commercial momentum.RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a pioneer in innovative life-support and di ...

Investors might want to bet on Inspira Technologies OXY B.H.N. Ltd. (IINN) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estim ...

RA'ANANA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. IINN ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it will present its HYLA blood sensor ("HYLA") to the global medical community for the first time. The presentation will take place at the U.S. ELSO Annual Conference in Washington, D.C., between September 27–30, 2025.This official unveiling follows the Company's recent announce ...

RA'ANANA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it will present its HYLA blood sensor (“HYLA”) to the global medical community for the first time. The presentation will take place at the U.S. ELSO Annual Conference in Washington, D.C., between September 27–30, 2025. This official unveiling follows the Company’s rece ...

核心观点 - Inspira Technologies宣布其HYLA血液传感器在最新性能测试阶段达到97.35%的准确率 支持即将向美国FDA提交的申请[1] - 该传感器设计用于解决手术室和重症监护中患者病情瞬息万变但当前血液检测结果延迟的问题 通过每秒连续监测关键血液参数实现实时预警[3] - 公司定位为商业阶段医疗设备企业 拥有FDA批准的INSPIRA ART100系统及新一代ART500开发计划 并通过HYLA平台拓展非侵入式监测市场[4] 技术性能 - HYLA传感器准确率达97.35% 较2025年3月临床研究初始数据显著提升[1] - 采用光学测量技术实现非侵入性监测 无需从患者身上抽血[6] - 提供每秒级连续数据监测 替代间歇性抽血检测方式[3][6] 产品定位 - 主要设计用于集成Inspira的ART设备系列 同时作为独立设备开发以覆盖更广泛的耗材市场[2] - 采用"剃须刀与刀片" recurring revenue model[2] - 模块化设计兼容现有医疗设备 目标全球每年200万例心脏手术患者群体[6] 应用场景 - 适用于心肺旁路、体外膜肺氧合、连续性肾脏替代治疗和透析等多种医疗程序[6] - 专注于手术室和重症监护场景的实时血液监测需求[3] 商业进展 - 最新测试结果确认设备符合美国和欧洲监管路径要求[2] - 已引起全球领先医疗技术公司的显著兴趣[3] - 公司拥有FDA批准的INSPIRA ART100系统 在美国获批用于心肺旁路 在美国境外获批用于ECMO程序[4] 公司背景 - Inspira Technologies是专注于先进呼吸支持和实时血液监测解决方案的商业阶段医疗设备公司[4] - 拥有不断增长的知识产权组合和战略精简的运营体系[4] - 近期内部调整反映与行业长期趋势的广泛对齐 包括整合、跨部门协作和潜在战略合作伙伴关系[4]